Executive Committee

Insoo Hyun, PhD, Director
Associate Professor of Bioethics

Dr. Hyun holds a BA and MA in Philosophy from Stanford, and a PhD in Philosophy from Brown University. Dr. Hyun is an internationally-recognized expert in stem cell research ethics and policy. From 2006 to 2010, Dr. Hyun served as the Chair of the Ethics and Public Policy Committee for the International Society for Stem Cell Research (ISSCR), the premier professional society for stem cell researchers worldwide. As Ethics Chair, Dr. Hyun has been a primary contributing author on ethics and policy advisory reports to the ISSCR leadership and members. From 2007-2009, he was Co-Chair of the ISSCR Task Force that drafted international guidelines for the clinical translation of stem cells. Prior to that, he was Chair of the ISSCR Subcommittee on Human Materials Procurement. This subcommittee drafted international guidelines for the procurement of embryos, ova, sperm, and body cells for the derivation of new stem cell lines. Dr. Hyun also drafted all the sample informed consent documents for human materials procurement for the scientific membership of the ISSCR. He has advised governmental scientific bodies in the U.S. (National Academy of Sciences), Australia, Argentina, Norway, China, Singapore, and South Korea on matters relating to the regulation of basic and translational stem cell research. His bioethics publications have appeared in Nature, Science, Cell Stem Cell, and many other top tier scientific journals. His book Bioethics and the Future of Stem Cell Research is forthcoming with Cambridge University Press.

Stuart J. Youngner, MD
Susan E. Watson Professor and Chair, Department of Bioethics.

Dr. Youngner is a nationally- and internationally-recognized scholar in Biomedical Ethics, and has published and spoken on topics including: decisions to limit life-sustaining treatment; ethics committees; physician-assisted suicide; advance directives; definitions of death; ethical issues in organ and tissue retrieval and transplantation. He has published over 90 articles in peer-reviewed scholarly journals. He is the editor or co-editor of eight books, including The Definition of Death: Contemporary Controversies (Johns Hopkins University Press). His latest book, Transplanting Human Tissue: Ethics, Policy and Practice, was published by Oxford University Press in September, 2003.

Dr. Youngner serves on the editorial advisory boards of the Journal of Medicine and Philosophy, the Kennedy Institute of Ethics Journal, and the Journal of Law, Medicine, and Ethics. He has been elected a Fellow of the Hastings Center and the American Psychiatric Association, and has been certified by the American Board of Psychiatry and Neurology. He has served as a consultant to the United States Congress Office of Technology Assessment, the Robert Wood Johnson Foundation, the Institute of Medicine, and the Pontifical Academy of Sciences. Dr. Youngner has testified before the United States Congress. He served as President of the Society for Bioethics Consultation from 1994-1997. He is a founding member of the Board of Directors of the American Society for Bioethics and Humanities, and was given the organization's Distinguished Service Award in 2000. He co-directed a national task force that examined the need for standards for ethics committees and clinical ethics consultation. He is the on the Medical Board of Trustees and ethics committee of the Musculoskeletal Transplant Foundation.

Stanton [Stan] L. Gerson, MD
Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, Director of the NCI-Designated Case Comprehensive Cancer Center, Director of the Ireland Cancer Center, and founding Director of the Ohio Wright Center for Stem Cell and Regenerative Medicine.

Dr. Gerson was Chief of the Division of Hematology/Oncology from 1995-2004 at University Hospitals of Cleveland and Case Western Reserve University. Dr. Gerson graduated from Harvard College [magna cum laude] and Harvard Medical School [cum laude], and performed his residency and fellowship training at the Hospital of the University of Pennsylvania. He has been at Case Western Reserve University since 1983. He has been active in the stem cell, hematologic malignancies, and developmental therapeutics programs. He has multiple NIH grants and over 197 publications, 247 abstracts, 26 book chapters, and 12 patents in stem cells and drug discovery. His honors include invited membership in the American Association of Physicians, and the Malinkrodt Scholar award. Dr Gerson is co-editor of the textbook Cancer Gene Therapy and the new text, Clinical Hematology, published in 2005. He serves on the External Advisory Boards for the Georgetown Cancer Center, the Moffitt Cancer Center, Sidney Kimmel Johns Hopkins Cancer Center, Holden Iowa Cancer Center, and the University of Chicago Cancer Center. Dr. Gerson has served as the Chair of the Experimental Therapeutics II and serves on the Program Project Study Section for the National Institutes of Health and on numerous other review bodies for the NIH.

Dr. Gerson's research interests are in the areas of stem cells and DNA repair. He developed mesenchymal stem cells as a therapeutic infusion for blood stem cell transplantation and for the correction of genetic disorders. This therapy is approaching FDA approval. He identified a gene therapy strategy method that creates drug resistant stem cells capable of selectively repopulating the recipient without the need for high dose toxic therapy. This strategy is now used experimentally and clinically throughout the country. He developed inhibitors of DNA repair to improve the efficacy of anti-cancer agents. Both are currently in clinical trials. Finally, Dr. Gerson has developed transgenic mouse models that examine the role of critical genes in the stability of stem cell populations over the lifetime of the animal. These studies may predict stem cell diseases of aging and cancer. His research has generated 12 patents in the area of gene therapy and cancer drug development that have been licensed to 3 companies.

His leadership of the Stem Cell Center and the Cancer Center involves coordinating research throughout the medical centers in Cleveland. He is also leading University Hospitals' effort to bring cancer care under one roof in the New Cancer Hospital scheduled to open in 2010.

Other Executive Committee Members TBA